Literature DB >> 12704689

Nipple aspirate fluid cytology in breast carcinoma.

Savitri Krishnamurthy1, Nour Sneige, Patricia A Thompson, Sylvie M Marcy, S Eva Singletary, Massimo Cristofanilli, Kelly K Hunt, Henry M Kuerer.   

Abstract

BACKGROUND: Nipple aspirate fluid (NAF) cytology is a simple noninvasive method to study cells exfoliated into the ductal system of the breast. In the current study, the significance of cytologic findings in NAF was determined by correlating them with histopathologic findings from corresponding breast tissue. Cytologic-histologic correlations of NAF were performed in only a few studies.
METHODS: Nipple aspirate fluid was collected by breast massaging and by using a breast aspiration device from 74 women with biopsy confirmed intraductal or invasive carcinoma with or without a history of preoperative neoadjuvant chemotherapy. Cytospin preparations were Pap stained. The number of epithelial cells was quantitated and foamy macrophages were semiquantitatively scored. Cytologic findings were categorized as insufficient for diagnosis (less than 10 epithelial cells), benign, mild atypia, marked atypia or suspicious, and malignant. Finally, they were correlated with tissue findings.
RESULTS: Nipple aspirate fluid was obtained from 74 women, including 24 who had received preoperative neoadjuvant chemotherapy. The median age of patients was 54 years. A mean volume of 57 microL NAF and a mean of 149 epithelial cells were obtained. Foamy macrophages were present in 51 (70%) of the specimens. There was a significant correlation between the presence of epithelial cells and foamy macrophages (P < 0.001). Patients treated with chemotherapy had fewer epithelial cells in their NAF compared with patients who were not treated with chemotherapy. Thirty specimens (41%) were inadequate for diagnosis, 34 were (46%) benign, 5 (7%) were mildly atypical, 1 (1%) was markedly atypical, and 4 (5%) were malignant. Of the five cases with mildly atypical cytology, three were intraductal papilloma, one was low-grade papillary intraductal carcinoma, and one was low-grade intracystic papillary carcinoma with invasion in the corresponding tissue specimen. The single case with markedly atypical NAF cytology had extensive ductal carcinoma in situ (DCIS). Of the four cases with malignant NAF cytology, two were extensive DCIS and two had invasive carcinoma with extensive DCIS in the breast specimen. Overall, 3 (27%) of 11 cases of DCIS were detected in NAF and only 2 (4%) of 52 invasive carcinomas including the only two cases with extensive DCIS were detected in NAF.
CONCLUSION: The probability of detecting malignant cells in NAF is dependent on the extent of DCIS and nipple involvement by DCIS. Nipple aspirate fluid is not a sensitive test for detecting invasive carcinoma of the breast. Atypical cytology in NAF is associated with papillary lesions in the underlying breast. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 12704689     DOI: 10.1002/cncr.10958

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  High levels of DJ-1 protein in nipple fluid of patients with breast cancer.

Authors:  Miki Oda; Masujiro Makita; Keiichi Iwaya; Futoshi Akiyama; Norio Kohno; Benio Tsuchiya; Takuji Iwase; Osamu Matsubara
Journal:  Cancer Sci       Date:  2012-04-04       Impact factor: 6.716

2.  Cytology in nipple aspirate fluid during a randomized soy food intervention among premenopausal women.

Authors:  Gertraud Maskarinec; Shana Suzuki; Ian S Pagano; Yukiko Morimoto; Adrian A Franke; Hormoz Ehya
Journal:  Nutr Cancer       Date:  2013-10-15       Impact factor: 2.900

3.  Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings.

Authors:  Edward R Sauter; Colette Wagner-Mann; Hormoz Ehya; Andres Klein-Szanto
Journal:  Cancer Detect Prev       Date:  2007-02-20

4.  Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.

Authors:  Susan A Higgins; Ellen T Matloff; David L Rimm; James Dziura; Bruce G Haffty; Bonnie L King
Journal:  Breast Cancer Res       Date:  2005-10-24       Impact factor: 6.466

5.  Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation.

Authors:  Gillian Mitchell; Yoland C Antill; William Murray; Judy Kirk; Elizabeth Salisbury; Geoffrey J Lindeman; Juliana Di Iulio; Alvin D Milner; Lisa Devereaux; Kelly-Anne Phillips
Journal:  Breast Cancer Res       Date:  2005-11-14       Impact factor: 6.466

Review 6.  The intraductal approach to the breast: raison d'être.

Authors:  Bonnie L King; Susan M Love
Journal:  Breast Cancer Res       Date:  2006-04-21       Impact factor: 6.466

Review 7.  Ductal approaches to assessment and management of women at high risk for developing breast cancer.

Authors:  Imogen Locke; Gillian Mitchell; Rosalind Eeles
Journal:  Breast Cancer Res       Date:  2004-01-26       Impact factor: 6.466

8.  "Signet-ring" cell invasive lobular carcinoma of the breast - accidental finding associated with intraductal papilloma: a case report.

Authors:  Valerija Blazicević; Blazenka Staklenac; Jozo Kristek; Marija Pajtler; Zlatko Krajinović; Damir Stimac; Zdravko Ivezić; Zdenka Kotromanović; Ilijan Tomas; Marta Biljan
Journal:  Cases J       Date:  2009-02-06

9.  Cytologic features of nipple aspirate fluid using an automated non-invasive collection device: a prospective observational study.

Authors:  Kerry A S Proctor; Leslie R Rowe; Joel S Bentz
Journal:  BMC Womens Health       Date:  2005-08-03       Impact factor: 2.809

10.  Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0.

Authors:  John P Jakupciak; Andrea Maggrah; Samantha Maragh; Jennifer Maki; Brian Reguly; Katrina Maki; Roy Wittock; Kerry Robinson; Paul D Wagner; Robert E Thayer; Ken Gehman; Teresa Gehman; Sudhir Srivastava; Alioune Ngom; Gabriel D Dakubo; Ryan L Parr
Journal:  BMC Cancer       Date:  2008-04-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.